IL200029A0 - Methods for the treatment of senile dementia of the alzheimer's type - Google Patents

Methods for the treatment of senile dementia of the alzheimer's type

Info

Publication number
IL200029A0
IL200029A0 IL200029A IL20002909A IL200029A0 IL 200029 A0 IL200029 A0 IL 200029A0 IL 200029 A IL200029 A IL 200029A IL 20002909 A IL20002909 A IL 20002909A IL 200029 A0 IL200029 A0 IL 200029A0
Authority
IL
Israel
Prior art keywords
alzheimer
treatment
methods
type
senile dementia
Prior art date
Application number
IL200029A
Other languages
English (en)
Original Assignee
Phenomenome Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomenome Discoveries Inc filed Critical Phenomenome Discoveries Inc
Publication of IL200029A0 publication Critical patent/IL200029A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
IL200029A 2007-02-08 2009-07-23 Methods for the treatment of senile dementia of the alzheimer's type IL200029A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88888307P 2007-02-08 2007-02-08
PCT/CA2007/001472 WO2008095275A1 (en) 2007-02-08 2007-08-27 Methods for the treatment of senile dementia of the alzheimer's type

Publications (1)

Publication Number Publication Date
IL200029A0 true IL200029A0 (en) 2010-04-15

Family

ID=39537686

Family Applications (1)

Application Number Title Priority Date Filing Date
IL200029A IL200029A0 (en) 2007-02-08 2009-07-23 Methods for the treatment of senile dementia of the alzheimer's type

Country Status (8)

Country Link
US (5) US9034923B2 (enExample)
EP (2) EP2117527B1 (enExample)
JP (1) JP5470050B2 (enExample)
AU (1) AU2007346587C1 (enExample)
CA (2) CA2620274C (enExample)
IL (1) IL200029A0 (enExample)
SG (1) SG173418A1 (enExample)
WO (1) WO2008095275A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2117527B1 (en) 2007-02-08 2020-06-17 Med-Life Discoveries LP Compounds for use in the treatment of senile dementia of the alzheimer's type
TWI475989B (zh) * 2008-12-22 2015-03-11 Phenomenome Discoveries Inc 縮醛磷脂類化合物,含彼之醫藥組成物以及治療老化疾病的方法
CA2774869C (en) 2009-10-01 2017-10-24 Phenomenome Discoveries Inc. Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11318277B2 (en) 2017-12-31 2022-05-03 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
CA3112564A1 (en) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC System and method of improving sleep
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
CN114236019B (zh) * 2022-02-24 2022-05-06 宝枫生物科技(北京)有限公司 脑白质病变的生物标志物的应用
CN118512461A (zh) * 2024-06-03 2024-08-20 东莞市第八人民医院(东莞市儿童医院) 一种母乳来源磷脂在防治支气管肺发育不良的应用
CN119876292B (zh) * 2025-03-27 2025-06-03 浙江省白马湖实验室有限公司 一种酰胺类缩醛磷脂化合物的制备方法及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009371A1 (en) 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
FR2736265B1 (fr) 1995-07-07 1997-09-26 Forgeot Marcel Nouvelles compositions a base de phosphoglycero ethers et leur utilisation dans le traitement des maladies neuro-degeneratives
US5731354A (en) 1996-05-06 1998-03-24 Clarion Pharmaceuticals Inc. Treatment for the inhibition of neuro-degenerative disease states
US6177476B1 (en) 1998-08-27 2001-01-23 Clarion Pharmaceuticals Inc. Nutritional supplements for replenishing plasmalogens
CA2298181C (en) 2000-02-02 2006-09-19 Dayan Burke Goodnough Non-targeted complex sample analysis
EP1285092A4 (en) 2000-04-14 2003-07-16 Metabolon Inc METHOD FOR DISCOVERY OF MEDICINES, DISEASE TREATMENT AND DIAGNOSIS USE THE METABOLOMICS
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
WO2002021139A2 (en) 2000-09-08 2002-03-14 Oxford Glycosciences (Uk) Ltd. Automated identification of peptides
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AU2002338348A1 (en) 2001-04-06 2002-10-21 Biovision Ag Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
EP1389306A2 (de) 2001-05-09 2004-02-18 BioVisioN AG Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien
NZ534751A (en) 2002-03-22 2007-05-31 Phenomenome Discoveries Inc Method of visualizing non-targeted metabolomic data generated from fourier transform ion cyclotron resonance mass spectrometers
JP2004026803A (ja) * 2002-03-29 2004-01-29 Nof Corp 神経細胞死予防剤
ES2311751T3 (es) 2002-08-23 2009-02-16 Bayer Healthcare Ag Biomarcadores de polipeptidos para la diagnosis de la enfermedad de alzheimer.
SE0203886D0 (sv) * 2002-12-27 2002-12-27 Ltp Lipid Technologies Provide Glycerolesterprodukt och dess användning
US20040191294A1 (en) * 2003-03-27 2004-09-30 Ramaprasad Talahalli Ravichandra Health composition
EP1637161A4 (en) * 2003-04-22 2007-06-27 Astellas Pharma Inc MEANS FOR THE TREATMENT OF NEURODEGENERATIVE ILLNESSES OF THE BRAIN WITH PPAR [delta] AGONIST
EP1694816B1 (en) 2003-11-07 2013-08-28 Ciphergen Biosystems, Inc. Biomarkers for alzheimer's disease
WO2005085838A2 (en) 2004-03-02 2005-09-15 Vanderbilt University Computational analysis of mass spectroscopic lipid data
WO2005116659A2 (en) 2004-05-18 2005-12-08 Neurodx, Llc Compositions and methods relating to alzheimer’s disease
WO2007002285A2 (en) * 2005-06-21 2007-01-04 The Trustees Of The University Of Pennsylvania Methods for treating neurological and psychiatric conditions
JP4176749B2 (ja) 2005-07-29 2008-11-05 学校法人帝京大学 疾病検査法
CA2772688A1 (en) 2005-09-12 2007-03-22 Phenomenome Discoveries Inc. Methods for the diagnosis of colorectal cancer and ovarian cancer health states
EP1932164B1 (en) 2005-09-15 2013-04-24 Phenomenome Discoveries Inc. Method and apparatus for fourier transform ion cyclotron resonance mass spectrometry
KR20080104350A (ko) 2006-02-28 2008-12-02 페노미넘 디스커버리스 인코포레이티드 치매 및 다른 신경 장애의 진단을 위한 방법
JP2009538416A (ja) 2006-05-26 2009-11-05 フェノメノーム ディスカバリーズ インク 多発性硬化症を診断するための生物マーカー、及びその方法
JPWO2008093709A1 (ja) 2007-01-30 2010-05-20 株式会社プロジェクト・エム アミロイド蛋白質の凝集抑制および分解促進によりアミロイドーシスと関連する疾患を予防または治療するための組成物
EP2117527B1 (en) 2007-02-08 2020-06-17 Med-Life Discoveries LP Compounds for use in the treatment of senile dementia of the alzheimer's type
US8026099B2 (en) 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders

Also Published As

Publication number Publication date
AU2007346587B2 (en) 2014-03-27
CA2620274A1 (en) 2008-06-20
SG173418A1 (en) 2011-08-29
US10123989B2 (en) 2018-11-13
US20160015673A1 (en) 2016-01-21
US20150306057A1 (en) 2015-10-29
EP2620147B1 (en) 2020-06-03
US9034923B2 (en) 2015-05-19
US9517222B2 (en) 2016-12-13
US20120129934A1 (en) 2012-05-24
CA2695167C (en) 2011-11-01
EP2117527A4 (en) 2012-09-12
EP2117527B1 (en) 2020-06-17
US20170056363A1 (en) 2017-03-02
JP5470050B2 (ja) 2014-04-16
JP2010518029A (ja) 2010-05-27
US20130046016A1 (en) 2013-02-21
EP2117527A1 (en) 2009-11-18
CA2620274C (en) 2011-10-04
AU2007346587C1 (en) 2015-01-22
US8993623B2 (en) 2015-03-31
EP2620147A2 (en) 2013-07-31
CA2695167A1 (en) 2008-06-20
WO2008095275A1 (en) 2008-08-14
AU2007346587A1 (en) 2008-08-14
EP2620147A3 (en) 2013-10-02

Similar Documents

Publication Publication Date Title
IL200029A0 (en) Methods for the treatment of senile dementia of the alzheimer's type
PT2985032T (pt) Glyx para utilização no tratamento da doença de alzheimer, doença de parkinson ou doença de huntington
ZA201006868B (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL190920A0 (en) Compounds for the treatment of metabolic disorders
IL190913A0 (en) Methods for the treatment of hyperhidrosis
EP1976377A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP1983972A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
IL188331A0 (en) Method for the treatment of acne
ZA200808963B (en) Compounds for the treatment of metabolic disorders
WO2011044537A9 (en) Methods for treating alzheimer's disease
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
IL192852A0 (en) Compounds for the treatment of metabolic disorders
ZA200804264B (en) Process for the preparation of ferri-succinylcasein
DE602006009764D1 (de) Terphenylderivate zur Alzheimerbehandlung
IL206107A0 (en) Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
IL195392A0 (en) Compounds for the treatment of metabolic disorders
IL192851A0 (en) Compounds for the treatment of metabolic disorders
EP1955698A4 (en) PREVENTIVE / THERAPEUTIC AGENT FOR ALZHEIMER DEMENTIA
HU0402017D0 (en) Environment-friend process for the synthesis of quaternary ammonio-steroids
EP2099476A4 (en) METHODS OF TREATING ALZHEIMER'S DISEASE
ZA200804778B (en) New process for the preparation of esomeprazole non-salt form
IL192982A0 (en) Compounds for the treatment of metabolic disorders
IL208127A0 (en) Ptph1 inhibitors for the treatment of alzheimer's disease
GB0724947D0 (en) Composition for the treatment of psychiatric disorders